Kane Biotech Second Quarter 2024 Earnings: CA$0.01 loss per share (vs CA$0.007 loss in 2Q 2023)
Kane Biotech (CVE:KNE) Second Quarter 2024 Results
Key Financial Results
- Net loss: CA$1.22m (loss widened by 39% from 2Q 2023).
- CA$0.01 loss per share (further deteriorated from CA$0.007 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Kane Biotech's share price is broadly unchanged from a week ago.
Risk Analysis
Be aware that Kane Biotech is showing 6 warning signs in our investment analysis and 4 of those are a bit concerning...
Valuation is complex, but we're here to simplify it.
Discover if Kane Biotech might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSXV:KNE
Kane Biotech
A biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.
Moderate with weak fundamentals.